HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

calsurf

extracted from lung washes of calves

Networked: 4 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chang, Liwen: 2 articles (04/2021 - 12/2019)
2.	Cheng, Hongbin: 2 articles (04/2021 - 12/2019)
3.	Pan, Rui: 2 articles (04/2021 - 12/2019)
4.	Rong, Zhihui: 2 articles (04/2021 - 12/2019)
5.	Xia, Shiwen: 2 articles (04/2021 - 12/2019)
6.	Zhu, Xiaofang: 2 articles (04/2021 - 12/2019)
7.	Chen, Liping: 1 article (04/2021)
8.	Han, Jun: 1 article (04/2021)
9.	Lang, Yujie: 1 article (04/2021)
10.	Li, Maojun: 1 article (04/2021)

Related Diseases

1.	Pneumonia (Pneumonitis) 04/01/2021 - "To determine whether bovine surfactant given in NARDS can improve oxygenation and survival rate, we conducted a multicenter, randomized trial between January 2018 and June 2019, and we compared Calsurf treatment to controls in neonates with pneumonia accompanied by NARDS. " 04/01/2019 - "To study the clinical effect of calsurf, a domestic exogenous pulmonary surfactant, in the treatment of severe neonatal infectious pneumonia. " 04/01/2019 - "In neonates with severe infectious pneumonia, calsurf treatment can significantly improve oxygenation, reduce the degree of pulmonary consolidation, and shorten the duration of mechanical ventilation and length of hospital stay. " 04/01/2021 - ": Calsurf acutely improved OI immediately after administration in pneumonia-induced NARDS; although, we observed no significant decrease in mortality, duration of ventilator or oxygen, or major morbidity. "
2.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 12/01/2019 - "A Multicentered Randomized Study on Early versus Rescue Calsurf Administration for the Treatment of Respiratory Distress Syndrome in Preterm Infants." 04/01/2021 - "Neonatal acute respiratory distress syndrome (NARDS) reflects pulmonary surfactant dysfunction, and the usage of bovine surfactant (Calsurf) supplement may therefore be beneficial. "
3.	Lung Injury 01/01/2020 - "The group of animals treated with 200 mg/kg of Poractant alfa showed a prolonged survival time and rate compared to untreated but ventilated controls, and significantly ameliorated lung injury compared to Calsurf at any dose, including 200 mg/kg. The overall outcomes suggest the pulmonary effects to be dose dependent for both preparations. "
4.	Newborn Respiratory Distress Syndrome 01/01/2020 - "Poractant alfa and Calsurf are two natural surfactants widely used in China for the treatment of neonatal respiratory distress syndrome, which are extracted from porcine and calf lungs, respectively. "
5.	Bronchopulmonary Dysplasia 12/01/2019 - "No differences were observed between early and rescue Calsurf treatment groups with respect to the reintubation rate within 72 hours of age and the incidence of bronchopulmonary dysplasia."

Related Drugs and Biologics

1.	Oxygen (Dioxygen)
2.	Surface-Active Agents (Surfactants)
3.	Pulmonary Surfactants (Pulmonary Surfactant)
4.	poractant alfa (Curosurf)

Related Therapies and Procedures

1.	Mechanical Ventilators (Ventilator)
2.	Artificial Respiration (Mechanical Ventilation)
3.	Length of Stay